NCCN History
A historical timeline of the NCCN from its founding in 1993 to the present day.
Related Articles
Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC
Atezolizumab and bevacizumab yielded a median OS of 14.0 months vs 14.6 months with tremelimumab followed by durvalumab, a retrospective cohort study found.
AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research: Past Recipients
Past recipients of this award are listed on this page.
Osimertinib linked to more therapy-related cardiac events than other TKIs for NSCLC
Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors.“Despite…
Nivolumab/Ipilimumab Approaches EU Approval in Unresectable or Advanced HCC
The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.
AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients
Discover emerging themes and early-stage clinical oncology pipelines at the second AACR Oncology Industry Partnership event.
5 articles suggested by Wafik El-Deiry – OncoDaily
5 articles suggested by Wafik El-Deiry / Adrià Bernat, Alexander J Lazar, Angie Chen, Arola Fortian, Biyuan Wang, Boqiang Lyu, cancer, Chia-Kuei Mo, Collin
Abstracts – 2025 ASTRO Annual Meeting – American Society for Radiation Oncology (ASTRO)
The Annual Meeting program will deliver the top science and education related to the field of radiation oncology.
Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial
Annals of Surgical Oncology – Neoadjuvant chemotherapy followed by surgery (NAC-S) is the standard therapy for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan.…
The intestinal microbiota and cellular therapy: implications for impact and mechanisms
Xie and Smith review the current understanding of the role of the microbiota and its diversity on responses to cellular therapies, including stem cell tran
